Meyahealth
HomeGeneticsGeneTET2 gene
Back to Gene
TET2 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

TET2 gene

The TET2 gene acts as a tumor suppressor and is essential for the proper development of blood cells in the bone marrow.

Overview

The TET2 gene (tet methylcytosine dioxygenase 2) provides instructions for the TET2 protein. While its exact function is still being studied, it is believed to regulate transcription—the first step in protein production. It plays a significant role in the production of blood cells from hematopoietic stem cells in the bone marrow. The protein acts as a tumor suppressor, preventing cells from growing and dividing in an uncontrolled manner.

Health Conditions Related to Genetic Changes

Somatic mutations (acquired during a person's lifetime) in the TET2 gene are associated with several blood and bone marrow disorders. These mutations typically result in a nonfunctional protein, which may lead to the uncontrolled growth of blood-forming cells.

Essential thrombocythemia

Associated with high numbers of platelets in the blood, which are cells involved in clotting.

Polycythemia vera

A disorder characterized by uncontrolled blood cell production; TET2 mutations are found in approximately 16 percent of affected individuals.

Primary myelofibrosis

A condition characterized by the development of scar tissue (fibrosis) in the bone marrow.

Other disorders

Somatic TET2 mutations are also linked to:

  • Leukemia (cancer of blood-forming cells).
  • Myelodysplastic syndrome (a disease of the blood and bone marrow).
  • Systemic mastocytosis.

Other Names

  • FLJ20032
  • KIAA1546
  • MGC125715
  • Probable methylcytosine dioxygenase TET2
  • Tet oncogene family member 2
  • TET2_HUMAN

Frequently Asked Questions

Patients with TET2‑mutated myeloid neoplasms generally have similar transplant outcomes to those without the mutation, but the mutation can persist in the graft and may be associated with a slightly higher relapse risk. Pre‑transplant disease control with hypomethylating agents and post‑transplant monitoring of mutant allele burden are strategies used to mitigate this risk.
TET2 mutations are common in both conditions and are generally associated with a modestly higher risk of disease progression to myelofibrosis or acute leukemia. While they do not change the initial diagnostic criteria, their presence may prompt closer hematologic monitoring (e.g., more frequent blood counts and bone‑marrow assessments) and earlier consideration of cytoreductive therapy if platelet or red‑cell counts rise rapidly.
TET2 mutations in these disorders are usually somatic (acquired) rather than inherited, so routine family screening is not recommended. However, if a patient has a germline TET2 variant (rare) or a strong family history of hematologic cancers, referral to a clinical genetics service for counseling and possible testing is appropriate.
Hypomethylating agents such as azacitidine or decitabine are standard first‑line treatments and appear to be equally effective in TET2‑mutated disease. In myelofibrosis, JAK inhibitors (ruxolitinib, fedratinib) improve symptoms and spleen size, and some data suggest better spleen response in TET2‑mutated cases. Clinical trials of mutant‑specific epigenetic modulators are ongoing.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ